Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report.

Valenti M, Gargiulo L, Ibba L, Bertuzzi A, Manara S, Toso F, Costanzo A, Narcisi A

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).

Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoruso F, Balato A, Bardazzi F, Brianti P, Brunasso G, Burlando M, Cagni AE, Caproni M, Carrera CG, Carugno A, Caudullo F, Cuccia A, Dapavo P, Di Brizzi EV, Dini V, Gaiani FM, Gisondi P, Guarneri C, Lasagni C, Licata G, Loconsole F, Marzano AV, Megna M, Mercuri SR, Musumeci ML, Orsini D, Ribero S, Ruffo Di Calabria V, Satolli F, Strippoli D, Travaglini M, Trovato E, Venturini M, Zichichi L, Valenti M, Costanzo A, Narcisi A

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals.

Paolino G, Narcisi A, Carugno A, Malagoli P, Di Nicola MR, Foti A, Bianchi VG, Locatelli AG, Sena P, Costanzo A, Mercuri SR, Valenti M

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).

Pinter A, Eyerich K, Costanzo A, Garrelts A, Schuster C, Mert C, Lampropoulou A, Fotiou K, Maul JT, Papp KA

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study.

Gargiulo L, Ibba L, Bianco M, Di Giulio S, Alfano A, Cascio Ingurgio R, Facheris P, Perugini C, Valenti M, Costanzo A, Narcisi A

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

Orsini D, Megna M, Assorgi C, Balato A, Balestri R, Bernardini N, Bettacchi A, Bianchelli T, Bianchi L, Buggiani G, Burlando M, Brunasso A, Caldarola G, Cameli N, Campanati A, Campione E, Carugno A, Chersi K, Conti A, Costanzo A, Cozzani E, Cuccia A, D'Amico D, Dal Bello G, Dall'Olio EG, Dapavo P, De Simone C, Di Brizzi EV, Di Cesare A, Dini V, Esposito M, Errichetti E, Fargnoli MC, Fiorella CS, Foti A, Fratton Z, Gaiani FM, Gisondi P, Giuffrida R, Giunta A, Guarneri C, Legori A, Loconsole F, Malagoli P, Narcisi A, Paolinelli M, Potestio L, Prignano F, Rech G, Rossi A, Skroza N, Trovato F, Venturini M, Richetta AG, Pellacani G, Dattola A

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).

Gargiulo L, Ibba L, Alfano A, Malagoli P, Amoruso F, Balato A, Barei F, Burroni AG, Caccavale S, Calzavara-Pinton P, Esposito M, Fargnoli MC, Ferrucci SM, Foti C, Girolomoni G, Gola M, Guanti MB, Gurioli C, Magliulo M, Maurelli M, Morrone P, Musumeci ML, Napolitano M, Ortoncelli M, Patruno C, Piraccini BM, Pezzolo E, Ribero S, Rossi M, Savoia P, Sciarrone C, Tirone B, Vaccino M, Veronese F, Costanzo A, Narcisi A

More than one effect in every affect.

Costanzo A, Musetti A, Rossi R, Schimmenti A

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaçi D

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study.

Ibba L, Di Giulio S, Gargiulo L, Facheris P, Perugini C, Costanzo A, Narcisi A, Valenti M